Navigating AML: Unraveling FLT3 Clonal Evolution for Better Patient Care

Navigating AML: Unraveling FLT3 Clonal Evolution for Better Patient Care

Key Findings from EHA 2024 in AML: Canadian Experts Weigh In
Icon Objectives

Learning Objectives

Upon completion of this program, participants will be able to:

  1. Recognize the care gaps and unmet need of patients with unresectable LA-SCCHN
  2. Describe alternative treatments for patients with unresectable LA-SCCHN and cisplatin ineligibility
  3. Summarize emerging therapies and investigational approaches for patients with unresectable LA-SCCHN
Icon Chair Speaker

Speakers

Dr. Anna Spreafico

This program has been made possible through unrestricted support from Astellas.

Studies/trials discussed:

  • Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase3 (FLT3) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia
  • CLEVO study
  • RATIFY trial
  • MORPHO trial
  • FLT3-ITD MICROCLONES ARE DETECTED AT RELAPSE IN PATIENTS WITH FLT3-ITD AML AFTER INTENSIVE CHEMOTHERAPY
Tagged